Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 44,400 shares, a decline of 54.6% from the February 13th total of 97,800 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average trading volume of 816,400 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 1.08% of ZyVersa Therapeutics at the end of the most recent quarter. 3.91% of the stock is owned by institutional investors.

ZyVersa Therapeutics Trading Down 1.4 %

Shares of NASDAQ ZVSA opened at $0.79 on Friday. ZyVersa Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $10.20. The stock has a fifty day moving average of $1.23 and a 200-day moving average of $1.60.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.